High-dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis

Pediatric Pulmonology

Volumn 49, Issue 2, 2014, Pages 148-153

  Lahiri, Thomas ^a   Guillet, Alyson ^a   Diehl, Sandra ^a   Ferguson, Michael ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

biomarkers; cystic fibrosis; ibuprofen; kidney injury

Indexed keywords

AMINOGLYCOSIDE; BIOLOGICAL MARKER; CREATININE; IBUPROFEN; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE;

ACUTE KIDNEY FAILURE; ADOLESCENT; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY INJURY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SCHOOL CHILD; URINALYSIS;

BIOMARKERS; CYSTIC FIBROSIS; IBUPROFEN; KIDNEY INJURY;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IBUPROFEN; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PILOT PROJECTS; PROTEINURIA; RECEPTORS, VIRUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892936544     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22795     Document Type: Conference Paper

References (43)

1. Davis PB, Drumm M, Konstan MW,. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229-1256.
2. Prayle A, Smyth AR,. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med 2010; 16: 604-610.
3. Prayle A, Watson A, Fortnum H, Smyth A,. Side effects of aminoglycosides on the kidney, ear, and balance in cystic fibrosis. Thorax 2010; 65: 654-658.
4. Vandewalle A, Farman N, Morin JP, Fillastre JP, Hatt PY, Bonvalet JP,. Gentamicin incorporation along the nephron: autoradiographic study on isolated tubules. Kidney Int 1981; 19: 529-539.
5. Bockenhauer D, Hug MJ, Kleta R,. Cystic fibrosis, aminoglycoside treatment and acute renal failure: the not so gentle micin. Pediatric Nephrol 2009; 24: 925-928.
6. Prestidge C, Chilvers MA, Davidson AG, Choo E, McMahon V, White CT,. Renal function in pediatric cystic fibrosis patients in the first decade of life. Pediatr Nephrol 2011; 26: 605-612.
7. Andrieux A, Haramba J, Bui S, Nacka F, Iron A, Lllanas B, Fayon M,. Renal impairment in children with cystic fibrosis. J Cyst Fibros 2010; 9: 263-268.
8. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ,. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39: 15-20.
9. Konstan MW, Byard PJ, Hoppel CL, Davis PB,. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
10. 1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 1084-1089.
11. Lands LC, Milner R, Cantin AM, Manson D, Corey M, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151: 249-254.
12. Lands LC, Stanojevic S,. Oral nonsteroidal anti-inflammatory drug therapy for cystic fibrosis [review]. Cochrane Database Syst Rev 2007; 4: CD001505.
13. Fennell PB, Quante J, Wilson K, Boyle M, Strunk R, Ferkol T,. Use of high-dose ibuprofen in a pediatric cystic fibrosis center. J Cyst Fibros 2007; 6: 153-158.
14. Cystic Fibrosis Foundation Patient Registry. 2010. Annual Data Report to the Center Directors. Bethesda, Maryland: Cystic Fibrosis Foundation; 2011.
15. Ulinski T, Guigonis V, Dunan O, Bensman A,. Acute renal failure after treatment with non-steroidal anti-inflammatory drugs. Eur J Pediatr 2004; 163: 148-150.
16. Bennett WM, Henrich WL, Stoff JS,. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28: S56-S62.
17. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW,. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370.
18. Radhakrishnan J, Kiryluk K,. Acute renal failure outcomes in children and adults. Kidney Int 2006; 69: 17-19.
19. Askenazi DJ, Feig DI, Graham NM, Hui-Stickle S, Goldstein SL,. 3-5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 2006; 69: 184-189.
20. Al-Aloul M, Jackson M, Bell G, Ledson M, Walshaw M,. Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients. J Cyst Fibros 2007; 6: 41-47.
21. Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D, Morgan TJ,. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dia Transplant 2003; 18: 543-551.
22. Liangos O, Tighiouart H, Perianayagam MC, Kolyada A, Han WK, Wald R, Bonventre JV, Jaber BL,. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14: 423-431.
23. Huang Y, Don-Wauchope A,. The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acute kidney injury: a systematic review. Inflamm Allergy Drug Targets 2011; 260-271.
24. Ferguson M, Waikar SS,. Emerging and Established Markers of Renal Fuction. Clin Chem 2012; 58: 680-689.
25. Vaidya V, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G, Matsouaka R, Betensky RA, Curhan GC, Bonventre JV,. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008; 1: 200-208.
26. Kunin CM, Chesney RW, Craig WA, Englans AC, DeAneglis C,. Enzymuria as a marker of renal injury and disease: studies of N-acteyl-beta-glucosaminidase in the general population and in patients with renal disease. Pediatrics 1978; 62: 751-760.
27. Price RG,. The role of NAG (N-acteyl-beta- d -glucosaminidase) in the diagnosis of kidney disease including the monitoring of neohrotoxicity. Clin Nephrol 1998; 38: S14-S19.
28. Glass S, Plant ND, Spencer DA,. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis. J Cyst Fibros 2005; 4: 221-225.
29. Olsen KM, Rudis MI, Rebuck J, Hara J, Gelmobnt D, Mehdian R, Nelson C, Rupp ME,. Effect of once-daily vs multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004; 32: 1678-1682.
30. Ring E, Eber E, Erwa W, Zach MS,. Urinary N-acetyl-beta- d -glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation. Arch Dis Child 1998; 78: 540-543.
31. Guy EL, Bosomworth M, Denton M, Conway SP, Brownlee KG, Lee TW,. Serum tobramycin level following delivery of tobramycin (Tobi) via eFlow advance nebulizer in children with cystic fibrosis. J Cyst Fibros 2010; 9: 292-295.
32. Zafivroska KG, Bogdanovska SV, Marina N, Gruev T, Lozance L,. Urinary excretion of three specific tubular enzymes in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). Renal Failure 1993; 15: 51-54.
33. Bonventre JV,. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant 2009; 24: 3265-3268.
34. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical qualification studies. Nat Biotechnol 2010; 28: 478-485.
35. Zhou Y, Vaidya VS, Brown RP, Zhang J, Rosenzweig BA, Thompson KL, Miller TJ, Bonventre JV, Goering PL,. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci 2008; 101: 159-170.
36. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008; 1: 200-208.
37. McWilliam SJ, Antoine DF, Sabbisetti V, Turner MA, Farragher T, Bonaventre JV, et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS ONE 2012; 7: e43898 (ePub 2012 Aug 24).
38. Uluer AZ, Casey A, Jawaid N, Fowler R, Demars N, Vaidya V, Waikar S, Bonventre JV, Ferguson M,. Urinary biomarkers for early detection of nephrotoxicity in cystic fibrosis. Pediatr Pulmonol 2010; S33: A278.
39. Dobson L, Stride A, Bingham C, Elworthy S, Sheldon CD, Hattersley AT, et al. Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. Pediatr Pulmonol 2005; 39: 103-107.
40. Yahiaoui Y, Jablonski M, Hubert D, Mosnier-Pudar H, Noel LH, Stern M, et al. Renal involvement in cystic fibrosis: disease spectrum and clinical relevance. Clin J Am Soc Nephrol 2009; 4: 921-928.
41. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittel L, et al. Cystic Fibrosis Pulmonary Guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969.
42. Kovesi TA, Swartz R, MacDonald N,. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med 1998; 338: 65-66.
43. Scott CS, Retsch-Bogart GZ, Henry MM,. Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen. Pediatr Pulmonol 2001; 31: 314-316.